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Abstract
Background:  Coronary heart disease (CHD) is a significant cause of health and economic burden. Secondary
prevention programs play a pivotal role in the treatment and management of those affected by CHD although
participation rates are poor due to patient, provider, health system and societal-level barriers. As such, there is a need
to develop innovative secondary prevention programs to address the treatment gap. Telephone-delivered care is
convenient, flexible and has been shown to improve behavioural and clinical outcomes following myocardial infarction
(MI). This paper presents the design of a randomised controlled trial to evaluate the efficacy of a six-month telephone-
delivered secondary prevention program for MI patients (ProActive Heart).
Methods: 550 adult MI patients have been recruited over a 14 month period (December 2007 to January 2009) through
two Brisbane metropolitan hospitals, and randomised to an intervention or control group (n = 225 per group). The
intervention commences within two weeks of hospital discharge delivered by study-trained health professionals ('health
coaches') during up to 10 × 30 minute scripted telephone health coaching sessions. Participants also receive a ProActive
Heart handbook and an educational resource to use during the health coaching sessions. The intervention focuses on
appropriate modification of CHD risk factors, compliance with pharmacological management, and management of
psychosocial issues. Data collection occurs at baseline or prior to commencement of the intervention (Time 1), six
months follow-up or the completion of the intervention (Time 2), and at 12 months follow-up for longer term outcomes
(Time 3). Primary outcome measures include quality of life (Short Form-36) and physical activity (Active Australia
Survey). A cost-effective analysis of the costs and outcomes for patients in the intervention and control groups is being
conducted from the perspective of health care costs to the government.
Discussion: The results of this study will provide valuable new information about an innovative telephone-delivered
cost-effective secondary prevention program for MI patients.
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Background
Coronary heart disease (CHD) is a major cause of morbid-
ity, mortality and economic burden in Australia and the
rest of the developed world [1]. Secondary prevention
programs, with a focus on risk factor management, have
been shown to play a pivotal role in the treatment and
management of those affected by CHD. The clinical bene-
fits of secondary prevention, or cardiac rehabilitation pro-
grams, include decreased total cardiac mortality (26%),
improved quality of life (QOL), and lower rates of rehos-
pitalisation [2,3]. As such, guidelines recommend that all
persons with CHD participate in secondary prevention
programs [4,5].
The traditional and most researched model of secondary
prevention consists of participants attending a group out-
patient cardiac rehabilitation program for several weeks,
including supervised physical activity and CHD risk factor
education [6]. However, participation rates in traditional
cardiac rehabilitation programs are less than optimal [7].
Witt et al. (2005) reported that in Australia 29% of eligi-
ble acute myocardial infarction (MI) patients were
referred to cardiac rehabilitation, and only 30% of those
referred actually attended, in the United States 29% of MI
patients participated, and in Japan only 21% of MI
patients participated [7].
Reported barriers to participation in traditional cardiac
rehabilitation programs include patient, provider, health
system and societal-level barriers such as: older age,
female gender, lower education level, a lack of perceived
benefit, work or time constraints, transport difficulties,
limited availability of programs, lack of reimbursement,
as well as limited social or family support [7,8]. Therefore,
there is an opportunity and challenge in Australia and
internationally to provide innovative CHD services to
overcome these barriers to participation, and address the
significant treatment gap.
Telephone-delivered interventions are convenient and
flexible; they can be delivered at a suitable time for the
participant and in their own home; and importantly they
improve behavioural outcomes following MI [8,9]. Whilst
telephone interventions cannot reach those without
access to a telephone, in Australia, approximately 96% of
the population live in a household with at least one tele-
phone connection [10]. There are a number of well
researched telephone-delivered interventions for CHD
patients [11-13] and a large body of literature on home-
based and telehealth programs for patients with heart fail-
ure [14] or diabetes [15]. Overall, these programs have
been shown to be clinically effective, and in a number of
cases, cost-effective as well; they also demonstrate high
acceptability to participants [16]. We have developed a
novel telephone-delivered secondary prevention program
that builds on this earlier work to overcome some of the
reported barriers to participation in, and adherence to,
currently available cardiac rehabilitation programs
(ProActive Heart).
We are trialling a state-of-the-art approach to the delivery
of secondary prevention for MI patients through: (i) the
recruitment and delivery approach used; (ii) the inclusion
of a theoretical framework; and (iii) the content of the
ProActive Heart program. First, participants are recruited
daily by hospital-based staff, to ensure the research team
capture all eligible program participants. ProActive Heart
is delivered by project-trained and highly skilled health
professionals, or 'Health Coaches', over the telephone.
The Health Coaches are based off-site which provides flex-
ibility around the translation of ProActive Heart into clin-
ical practice either utilising telehealth lines or helplines
available to CHD patients (such as the Heart Foundation's
'Heartline' in Australia) [17] or through acute clinical set-
tings.
Second, theory-based health behaviour interventions are
known to be more effective than those that are not theo-
retically-based [18]. ProActive Heart is grounded in Social
Cognitive Theory which has been successfully used across
a wide range of health behaviour interventions [18].
ProActive Heart has a focus on the core determinants of
health behaviour including: knowledge of the risks and
benefits of the behaviour; self efficacy or confidence that
one can engage in the behaviour under various circum-
stances; outcome expectations; and specific strategies for
achieving positive health behaviour change [19,20]. Par-
ticipants develop a personalized action plan (incorporat-
ing goal setting) and identification of support networks to
enhance behaviour change maintenance. Health Coaches
emphasise the benefits of practicing the recommended
behaviour, support participants in setting incremental
goals to reach the recommended behaviour, with a focus
on overcoming self-reported barriers; and provide encour-
agement to achieve the goal. The intervention targets for
addressing individual CHD risk factors are derived from
existing national guidelines for the secondary prevention
of CHD [5].
Third, in addition to the lifestyle and medical education
and support provided by traditional cardiac rehabilitation
programs, we have included psychosocial support (with a
focus on depression and social isolation) based on the
strong and consistent evidence for an independent causal
association between depression, social isolation and lack
of quality social support and the causes and prognosis of
CHD [21].
This paper presents the design of a randomised controlled
trial (RCT) to evaluate the efficacy of ProActive Heart toBMC Cardiovascular Disorders 2009, 9:16 http://www.biomedcentral.com/1471-2261/9/16
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improve the coronary risk factor profile and quality of life
of MI patients, as well as cost-effectiveness of the program.
We hypothesize that participants in the intervention
group will have greater improvements in CHD risk factor
behaviours and quality of life, than those in the control
group. Additionally, we hypothesise that the ProActive
Heart program will be cost-effective compared to the con-
trol condition. The results of this study will provide valu-
able new information about an innovative cost-effective
secondary prevention program for CHD patients.
Methods/Design
Study Design
The study is a two group prospective RCT in which 550 MI
patients are randomised to the intervention (ProActive
Heart) or control group. Participants in both groups com-
plete assessments at baseline (Time 1), post-intervention
or 6 months follow-up (Time 2), and at 12 months fol-
low-up for longer term effects (Time 3).
Study Aims
i. To investigate the effects of ProActive Heart on
health outcomes [primary outcome variables include
quality of life (QOL) and physical activity] post-inter-
vention (Time 2), and at 12 months follow-up (Time
3) for longer term effects.
ii. To examine the cost-effectiveness of ProActive
Heart.
Sample Recruitment Procedures
Ethics approval was received from Human Research Ethics
Committees of The Prince Charles Hospital (EC2738), the
Royal Brisbane and Women's Hospital (2007/049), and
Monash University (2007/0584MC). We have recruited
550 adult MI patients over a 14 month period (December
2007 to January 2009) from two large metropolitan hos-
pitals in Brisbane, Australia (Royal Brisbane and
Women's, and The Prince Charles Hospitals). Recruit-
ment staff approached patients in hospital to provide
information about the study requirements and assess
them for eligibility. Eligible patients who initially agreed
to participate were given a description of the study and, if
still interested, provided written informed consent, in the
presence of a witness, prior to baseline assessment.
Participants were randomly assigned to the intervention
or control groups following enrolment (n = 225 in each
group). Sample size analysis indicated that 129 subjects
per group (intervention and control) or a total of 258
were required to detect, with 90% power and type I error
of 5% (two-tailed), an absolute intervention effect of 20%
or greater (based on a primary outcome variable of under-
taking the recommended level of physical activity [5], of
44% of control and 69% of the intervention over the
study period[13]). Sample size was significantly increased
above 258 to allow for participant drop-out and subgroup
analyses at follow-up. Eligibility criteria included: a diag-
nosis of MI [typical rise in serum level of troponin with at
least one of the following: ischaemic symptoms; develop-
ment of pathological Q waves on the ECG; ECG changes
indicative of ischaemia (ST-segment elevation or depres-
sion); or coronary artery intervention] [22]; adults aged
18–80 years; ability to understand English; availability via
telephone during the duration of the trial; and no other
medical condition that would interfere with optimal par-
ticipation or produce a significant risk to the patient as
defined by the referring specialist.
The intervention commences within the first two weeks of
discharge delivered from the Cancer Council Queensland.
A letter is mailed to the patient's primary care provider/s
informing them of the aims of the study, the patient's
agreement to participate and the information that may be
required from the patient and the care provider at follow-
up. To facilitate comparison of participants and non-par-
ticipants, de-identified demographic and simple health
status data are collected on a sub-sample of eligible MI
patients identified by the hospital during the study
period, and reasons for refusal are collected by the recruit-
ment staff.
Study conditions
Control
Control participants receive an existing written educa-
tional resource ('My Heart My Life')[23]; containing infor-
mation about CHD and the associated risk factors. 'My
Heart My Life' is produced by the Heart Foundation, and
provided to all acute coronary syndrome patients in
Queensland. They are also sent a quarterly informative
newsletter based on existing written educational materials
to enhance participant retention.
Intervention
Over a six month period, the intervention participants
receive up to 10 × 30 minute scripted telephone health
coaching sessions from a qualified health professional or
'health coach'. Health coaches are guided by a web-based
computer application and key enter all session informa-
tion. Prior to the commencement of the intervention, par-
ticipants are posted a ProActive Heart handbook outlining
the program goals for CHD risk factors [5], as well as the
benefits of improving CHD risk factors. The handbook
assists with personal assessment and goal setting that is
relevant to the sessions being delivered by the health
coach. Participants are also provided with the Heart Foun-
dation educational resource, 'My Heart My Life' [23] and
a tape measure for measurement of waist circumference.
The participant is encouraged to contact their usual health
care providers immediately if there are any medical con-BMC Cardiovascular Disorders 2009, 9:16 http://www.biomedcentral.com/1471-2261/9/16
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cerns during the course of the intervention (e.g. changes
in cardiac symptoms). Participants requiring additional
psychosocial support are triaged and put through to the
Helpline based at the Cancer Council Queensland in
order to be supported by a trained counsellor.
The health coaching sessions are based on the current
guidelines for CHD [5] with a focus on:
1) Appropriate reduction of clinical risk factors (hyperc-
holesterolaemia, hypertension and diabetes),
2) Appropriate modification of behavioural risk factors
(smoking, nutrition, alcohol, physical activity, weight
management),
3) Compliance with pharmacological management, and
4) Management of psychosocial issues (depression and
social isolation).
The sessions include an introductory session to explain
the program and what is expected of the participant, fol-
lowed by three weekly sessions, three fortnightly sessions
and four monthly sessions over six months to assist with
CHD risk factor management. The frequency of calls
decreases over the intervention period to encourage main-
tenance of behaviour change and self-management. Fol-
lowing the introductory call, the remaining calls are
structured as follows: (i) introduction and identification
of any cardiac symptom changes; (ii) assessment and
health coaching on relevant CHD risk factors; (iii) follow-
up on progress towards previous actions and goals; and
(iv) session review, including a summary of actions
required and scheduling of the next session. Consistent
with the self-management approach underpinning the
intervention, participants are encouraged to follow-up rel-
evant issues with their usual health care providers. The
health coach encourages and recommends the involve-
ment of significant others (i.e. the activation of social and
family support), as well as the activation of community
and environmental supports to enhance maintenance of
behaviour change (e.g. encouraging participants to utilise
local gyms or swimming pools).
Study Integrity
The study design is guided by the CONSORT statement
[24], and randomisation to study condition occurs fol-
lowing the completion of Time 1 assessment. Project staff
tracking data collection are blinded to condition. Strati-
fied randomisation occurs using a separate block ran-
domisation list that is generated for each subgroup or
strata, and randomisation is undertaken by the study
manager and concealed from investigators. The schedule
is stratified by gender to allow for the expected gender
imbalance (70% male, 30% female based on hospital sep-
aration data). The intervention protocol is manualised,
and all intervention calls are audio-taped with a propor-
tion reviewed to ensure adherence to the delivery of the
intervention protocol. All analyses will be conducted on
the basis of intention to treat.
Measurement
Medical or clinical information is collected at Time 1 from
hospital medical records (blood pressure, cholesterol
level, HbA1c, family history of heart disease, height,
weight, body mass index (BMI), procedures done or due,
GP details, cardiologist, hospital transferred from, admis-
sion and expected discharge date). Additional data is col-
lected at Time 1, Time 2 and Time 3 by computer assisted
telephone interview (CATI) using the web-based compu-
ter application (see Table 1). Health care utilisation data
is validated for 10% of study participants from GP and
hospital medical records.
Program Implementation
To assess program implementation, we measure satisfac-
tion by self-administered questionnaire at Time 2, and
participant adherence to the intervention by data col-
lected from the web-based computer application. Self-
administered satisfaction questions include: 'how would
you rate the ProActive Heart Handbook' (excellent to poor);
'how would you rate your sessions with the Health Coach'
(very useful to not useful at all); 'how would you rate the
Heart Foundation educational resource My Heart My Life'
(excellent to poor); 'did you get what you expected from the
program' (yes definitely to no definitely not); 'to what extent
has ProActive Heart met your needs' (almost all of my needs
have been met to none of my needs have been met); 'has
ProActive Heart helped you to deal more effectively with
your health issues' (yes it helped a great deal to no it seemed
to make things worse); 'in general how satisfied are you with
ProActive Heart (very satisfied to quite dissatisfied); 'were
you satisfied with the length of the health coaching ses-
sions' (yes, no); 'were you satisfied with the number of
health coaching sessions' (yes, no); and 'were you satisfied
with the length of the intervention overall' (yes, no). Par-
ticipants are also asked to highlight the strengths and
weaknesses of ProActive Heart in two open-ended ques-
tions. Participant adherence to ProActive Heart is assessed
by: the proportion of sessions completed during the inter-
vention period; the topics covered in each session; and the
total length (minutes) of intervention exposure during the
six month period.
Sociodemographics
Self-reported socio-demographic variables include: gen-
der, age, ethnicity, income, education, employment sta-
tus, and private health insurance status. At follow-up,
participants are requested to collect medical informationBMC Cardiovascular Disorders 2009, 9:16 http://www.biomedcentral.com/1471-2261/9/16
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(blood pressure, cholesterol level, HbA1c, BMI) from
their primary practitioner medical records prior to CATI.
Primary and Secondary Outcome Variables
Primary outcome variables include QOL [25] and physi-
cal activity [29]. Secondary outcome variables include:
nutrition [30], smoking, BMI, waist circumference, alco-
hol intake [30], psychosocial management (depression
[31] and social support [32]), angina [34], lipid profile,
blood pressure, diabetes management (HbA1c), and
pharmacological management [33]. The measures for
each of these outcome variables are summarised in Table
1.
Cost-Effectiveness
A cost-effectiveness analysis of the costs and outcomes for
patients in the intervention and control groups is con-
ducted from the perspective of health care costs to the gov-
Table 1: Measurement of outcome variables at baseline (Time 1), post-intervention (Time 2), and 12 months follow-up (Time 3)
Targets based on Heart Foundation 
guidelines [5]
Instrument
Primary Outcome Variables
Quality of Life Improvement in Health-related Quality of Life Short Form 36 [25]
Physical Activity At least 30 minutes of moderate intensity 
physical activity on five or more days per week 
(150 minutes minimum)
Active Australia Survey [29]
Secondary Outcome Variables
Nutrition Establish/maintain healthy eating patterns, with 
saturated and trans fatty acid ≤8% of total 
energy intake
Cancer Council of Victoria Food Frequency 
Questionnaire (CCVFFQ)[30]
Body mass index (BMI) and waist 
circumference
Waist measurement ≤ 94 cm (males) or ≤ 80 
cm (females) and BMI <25 kg/m2
Self Report
Alcohol Low risk consumption CCVFFQ
Smoking Complete cessation
Avoid passive smoking
Self report
Psychosocial management Improvement in depression and decreased 
social isolation
Hospital Anxiety and Depression Scale [31]
ENRICHD Social Support Instrument [32]
Blood Lipids Total blood cholesterol<4.0 mmol/l; LDL-
cholesterol <2.5; HDL-cholesterol > 1.0 mmol/
l; Triglycerides < 2.0 mmol/l
Medical records
Blood pressure Adults≥65: <140/90 mmHg), adults<65: <130/
85 mmHg 
(dependent on age, presence of diabetes, 
proteinuria and renal insufficiency)
Medical Records
Glycaemic Control Identify undiagnosed Type 2 diabetes; maintain 
optimal blood glucose level in those with 
diabetes (HbA1c1 ≤ 7%)
Medical Records
Pharmacological Management Anti-platelet agents, ACE2 Inhibitors, Beta-
blockers, Statins, Anticoagulants
Medication Compliance
Medical Records
Morisky Medication Compliance Survey [33]
Angina Controlled Angina Seattle Angina Questionnaire [34]
1. Glycosylated haemoglobin.
2. Angiotensin converting enzyme inhibitor.BMC Cardiovascular Disorders 2009, 9:16 http://www.biomedcentral.com/1471-2261/9/16
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ernment. Detailed self-reported data on costs of health
care utilisation (HCU) and medication is collected from
both intervention and control groups. HCU data is vali-
dated from a randomised sub-sample of 10% of patient
records and provider surveys. All resources utilised is mul-
tiplied by the appropriate cost using nationally applicable
cost data (eg. DRG costs for hospital admissions). The pri-
mary health outcome for the cost-effectiveness analyses is
quality-adjusted life years (QALYs). These are calculated
for both groups using QOL scores from the SF-36 [25] and
converted to utility scores using the SF-6D [26]. The meas-
ure of relative value for money from the intervention is
the incremental cost-effectiveness ratio calculated from
the additional cost for a gain in QALY's. A responder anal-
ysis is undertaken around the secondary endpoints for the
additional cost per responder. Probabilistic and one-way
analysis is undertaken around the parameters with uncer-
tainty and/or variability [27].
Data Analysis
Preliminary analyses establishes the degree of success of
the randomisation, and if there are any imbalances of
characteristics between the two groups, these are adjusted
for in the main analytical modelling. The intervention
effect is tested with repeated measures regression models
(with baseline scores as co-variates) fitted to estimate
changes over time and differences by group in changes
over time. A generalised estimating equations approach
(SUDAAN statistical package) is used to analyse missing
data, accommodating the analysis of partially complete
data records. Results are expressed as estimated mean
changes in QOL and physical activity outcomes by group
as an overall mean excess intervention over usual care
effect, all with corresponding 95% confidence intervals.
Heirarchical models may also be constructed to describe
data collected at different scales (measure, subject, hospi-
tal, regional, etc) and incorporate important sources of
uncertainty about the parameters of interest, and adjust-
ment for recruitment biases [28].
Discussion
This study provides critical information on a state-of-the-
art telephone delivered and cost-effective secondary pre-
vention program for MI patients. To date, this innovative
approach has not been tested by RCT with a cost effective-
ness analyses. Further, the study is sufficiently powered to
allow for subgroup and secondary analyses. The interven-
tion may be utilised by trained health professionals in a
range of settings including broad reach tele-health lines or
in acute health settings. As such, the outcomes of this
project may be immediately translated in to practice to
improve the health outcomes for those affected by CHD.
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